Aventis correction
This article was originally published in The Tan Sheet
Executive Summary
The company says it is not in any early stage evaluation of Nasocort as an Rx-to OTC switch candidate. "The Tan Sheet" reported in "Health News Daily" Wed. May 5 that Aventis was looking as Nasocort as a prospect...